Quantinno Capital Management LP Makes New $431,000 Investment in Kestra Medical Technologies, Ltd. $KMTS

Quantinno Capital Management LP acquired a new stake in shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 21,633 shares of the company’s stock, valued at approximately $431,000.

Other institutional investors have also made changes to their positions in the company. Farther Finance Advisors LLC acquired a new stake in shares of Kestra Medical Technologies during the fourth quarter valued at approximately $31,000. Russell Investments Group Ltd. boosted its stake in Kestra Medical Technologies by 43.5% in the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after purchasing an additional 474 shares during the period. BNP Paribas Financial Markets boosted its stake in Kestra Medical Technologies by 148.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after purchasing an additional 1,638 shares during the period. Daiwa Securities Group Inc. purchased a new position in Kestra Medical Technologies during the 4th quarter worth approximately $72,000. Finally, Brown Brothers Harriman & Co. raised its stake in Kestra Medical Technologies by 26.8% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after purchasing an additional 656 shares during the period.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. JPMorgan Chase & Co. assumed coverage on Kestra Medical Technologies in a report on Monday, August 10th. They issued an “overweight” rating and a $30.00 target price for the company. Wall Street Zen upgraded Kestra Medical Technologies from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. BTIG Research upped their price target on Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Weiss Ratings raised Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Finally, Wolfe Research set a $30.00 price objective on Kestra Medical Technologies in a research report on Wednesday, July 15th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Kestra Medical Technologies presently has a consensus rating of “Hold” and an average price target of $28.14.

Kestra Medical Technologies Stock Down 1.0%

Kestra Medical Technologies stock opened at $26.99 on Friday. Kestra Medical Technologies, Ltd. has a twelve month low of $15.42 and a twelve month high of $30.00. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41. The firm has a market cap of $1.58 billion, a PE ratio of -11.15 and a beta of 0.58. The firm’s 50 day moving average price is $24.57 and its two-hundred day moving average price is $22.80.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The company had revenue of $28.64 million for the quarter. On average, research analysts predict that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current fiscal year.

Insider Buying and Selling at Kestra Medical Technologies

In other Kestra Medical Technologies news, insider Traci S. Umberger sold 3,580 shares of the company’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $24.04, for a total value of $86,063.20. Following the transaction, the insider directly owned 195,825 shares of the company’s stock, valued at $4,707,633. This represents a 1.80% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Vaseem Mahboob sold 26,287 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $25.88, for a total value of $680,307.56. Following the sale, the chief financial officer directly owned 60,609 shares of the company’s stock, valued at $1,568,560.92. This trade represents a 30.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 238,164 shares of company stock valued at $5,700,952 in the last quarter. Corporate insiders own 5.30% of the company’s stock.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.